EP1404702A4 - Human secreted proteins - Google Patents

Human secreted proteins

Info

Publication number: EP1404702A4
Authority: EP; European Patent Office
Prior art keywords: secreted proteins; human secreted; human; proteins; secreted
Prior art date: 2001-03-21
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP02759068A

Other languages

German (de)

French (fr)

Other versions

EP1404702A2 (en

Inventor

Craig A Rosen

Steven M Ruben

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Human Genome Sciences Inc

Original Assignee

Human Genome Sciences Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-03-21

Filing date

2002-03-19

Publication date

2009-07-08

2002-03-19 Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc

2004-04-07 Publication of EP1404702A2 publication Critical patent/EP1404702A2/en

2009-07-08 Publication of EP1404702A4 publication Critical patent/EP1404702A4/en

Status Withdrawn legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pulmonology (AREA)
Diabetes (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Genetics & Genomics (AREA)
Endocrinology (AREA)
Obesity (AREA)
Toxicology (AREA)
Zoology (AREA)
Emergency Medicine (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Hematology (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

EP02759068A 2001-03-21 2002-03-19 Human secreted proteins Withdrawn EP1404702A4 (en)

Applications Claiming Priority (7)

Application Number	Priority Date	Filing Date	Title
US27734001P	2001-03-21	2001-03-21
US277340P		2001-03-21
US30617101P	2001-07-19	2001-07-19
US306171P		2001-07-19
US33128701P	2001-11-13	2001-11-13
US331287P		2001-11-13
PCT/US2002/009785 WO2002095010A2 (en)	2001-03-21	2002-03-19	Human secreted proteins

Publications (2)

Publication Number	Publication Date
EP1404702A2 EP1404702A2 (en)	2004-04-07
EP1404702A4 true EP1404702A4 (en)	2009-07-08

Family

ID=27402891

Family Applications (7)

Application Number	Title	Priority Date	Filing Date
EP02749512A Withdrawn EP1381622A2 (en)	2001-03-21	2002-03-19	Human secreted proteins
EP02760994A Withdrawn EP1379132A4 (en)	2001-03-21	2002-03-19	Human secreted proteins
EP02782476A Withdrawn EP1414845A4 (en)	2001-03-21	2002-03-19	Human secreted proteins
EP02799146A Withdrawn EP1390390A4 (en)	2001-03-21	2002-03-19	Human secreted proteins
EP02759068A Withdrawn EP1404702A4 (en)	2001-03-21	2002-03-19	Human secreted proteins
EP02723499A Withdrawn EP1379264A4 (en)	2001-03-21	2002-03-19	Human secreted proteins
EP02780789A Withdrawn EP1423134A2 (en)	2001-03-21	2002-03-19	Human secreted proteins

Family Applications Before (4)

Application Number	Title	Priority Date	Filing Date
EP02749512A Withdrawn EP1381622A2 (en)	2001-03-21	2002-03-19	Human secreted proteins
EP02760994A Withdrawn EP1379132A4 (en)	2001-03-21	2002-03-19	Human secreted proteins
EP02782476A Withdrawn EP1414845A4 (en)	2001-03-21	2002-03-19	Human secreted proteins
EP02799146A Withdrawn EP1390390A4 (en)	2001-03-21	2002-03-19	Human secreted proteins

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
EP02723499A Withdrawn EP1379264A4 (en)	2001-03-21	2002-03-19	Human secreted proteins
EP02780789A Withdrawn EP1423134A2 (en)	2001-03-21	2002-03-19	Human secreted proteins

Country Status (4)

Country	Link
EP (7)	EP1381622A2 (en)
AU (6)	AU2002363296A1 (en)
CA (7)	CA2441755A1 (en)
WO (7)	WO2002095010A2 (en)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7196164B2 (en)	1997-07-08	2007-03-27	Human Genome Sciences, Inc.	Secreted protein HHTLF25
CA2295474A1 (en)	1997-07-08	1999-01-21	Human Genome Sciences, Inc.	123 human secreted proteins
US20060052321A1 (en)	2002-04-05	2006-03-09	Raitano Arthur B	Nucleic acid and corresponding protein entitled 98P4B6 useful in treatment and detection of cancer
US6833438B1 (en)	1999-06-01	2004-12-21	Agensys, Inc.	Serpentine transmembrane antigens expressed in human cancers and uses thereof
US20040141975A1 (en)	1998-06-01	2004-07-22	Raitano Arthur B.	Nucleic acid and corresponding protein entitled 98P4B6 useful in treatment and detection of cancer
US20030149531A1 (en)	2000-12-06	2003-08-07	Hubert Rene S.	Serpentine transmembrane antigens expressed in human cancers and uses thereof
WO1999062941A2 (en)	1998-06-01	1999-12-09	Urogenesys, Inc.	Serpentine transmembrane antigens expressed in human cancers and uses thereof
EP1141027A1 (en)	1999-01-15	2001-10-10	Biogen, Inc.	Antagonists of tweak and of tweak receptor and their use to treat immunological disorders
US7335731B2 (en)	2000-07-25	2008-02-26	Genentech, Inc.	PRO4332 polypeptides
EP1666490A3 (en) *	2000-07-25	2006-11-02	Genentech, Inc.	Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1364021A2 (en)	2000-10-31	2003-11-26	Diadexus, Inc.	Compositions and methods relating to colon specific genes and proteins
US20020111302A1 (en) *	2000-11-30	2002-08-15	Y. Tom Tang	Novel nucleic acids and polypeptides
EP2280030A3 (en)	2001-04-10	2011-06-15	Agensys, Inc.	Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers
US20030119112A1 (en)	2001-06-20	2003-06-26	Genentech, Inc.	Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
US7494646B2 (en)	2001-09-06	2009-02-24	Agensys, Inc.	Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
ES2532757T3 (en)	2001-09-06	2015-03-31	Agensys, Inc.	Nucleic acid and corresponding protein called STEAP-1 useful in the treatment and detection of cancer
CA2463596A1 (en)	2001-10-12	2003-04-24	Yamanouchi Pharmaceutical Co., Ltd.	Method of screening cell death inhibitor
PT1997512E (en)	2002-04-09	2014-02-20	Biogen Idec Inc	Methods for treating tweak-related conditions
AU2003900747A0 (en) *	2003-02-18	2003-03-06	Garvan Institute Of Medical Research	Diagnosis and treatment of pancreatic cancer
US20050025763A1 (en)	2003-05-08	2005-02-03	Protein Design Laboratories, Inc.	Therapeutic use of anti-CS1 antibodies
US7709610B2 (en)	2003-05-08	2010-05-04	Facet Biotech Corporation	Therapeutic use of anti-CS1 antibodies
WO2005019258A2 (en) *	2003-08-11	2005-03-03	Genentech, Inc.	Compositions and methods for the treatment of immune related diseases
PT2380985E (en)	2003-09-23	2014-03-26	Univ North Carolina	Cells expressing vitamin k epoxide reductase and use thereof
WO2005040367A1 (en) *	2003-10-14	2005-05-06	Baxter International Inc.	Vitamin k epoxide recycling polypeptide vkorc1, a therapeutic target of coumarin and their derivatives
WO2005076003A2 (en) *	2004-02-03	2005-08-18	Bayer Healthcare Ag	Diagnostics and therapeutics for diseases associated with plasma glutamate carboxypeptidase (pgcp)
US20050186577A1 (en)	2004-02-20	2005-08-25	Yixin Wang	Breast cancer prognostics
PL1742966T3 (en)	2004-04-22	2014-04-30	Agensys Inc	Antibodies and molecules derived therefrom that bind to steap-1 proteins
EP2305693B1 (en) *	2004-09-01	2015-07-15	Dynavax Technologies Corporation	Methods and compositions for inhibition of innate immune responses and autoimmunity
WO2006026807A1 (en) *	2004-09-07	2006-03-16	Telethon Institute For Child Health Research	Agents for treatment or prevention of an allergic disorder
US20080227089A1 (en) *	2004-09-07	2008-09-18	Telethon Institute For Child Health Research	Method of Diagnosing and/or Predicting the Development of an Allergic Disorder
DK2332408T3 (en)	2005-02-17	2013-12-02	Biogen Idec Inc	Treatment of neurological diseases
CA2599284A1 (en)	2005-02-28	2006-08-31	Baxter International Inc.	Recombinant co-expression of vitamin k epoxide reductase subunit 1 to improve vitamin k dependent protein expression
CA2601574C (en)	2005-03-15	2014-12-02	University Of North Carolina At Chapel Hill	Methods and compositions for producing active vitamin k-dependent proteins
CA2607697C (en)	2005-05-10	2015-01-06	Biogen Idec Ma Inc.	Treating and evaluating inflammatory disorders
WO2006138219A2 (en)	2005-06-13	2006-12-28	Biogen Idec Ma Inc.	Methods of diagnosis / prognosis of inflammatory conditions
CA2620809A1 (en) *	2005-09-01	2007-03-08	Howard Florey Institute Of Experimental Physiology And Medicine	Prophylactic and therapeutic agents and uses therefor
GB0521488D0 (en) *	2005-10-21	2005-11-30	Ares Trading Sa	Integral membrane protein
US7572618B2 (en)	2006-06-30	2009-08-11	Bristol-Myers Squibb Company	Polynucleotides encoding novel PCSK9 variants
RU2639543C9 (en)	2006-10-27	2018-06-14	Дженентек, Инк.	Antibodies and immunoconjugates and their applications
CA2667894A1 (en)	2006-11-07	2008-05-15	Merck & Co., Inc.	Antagonists of pcsk9
US8093222B2 (en)	2006-11-27	2012-01-10	Isis Pharmaceuticals, Inc.	Methods for treating hypercholesterolemia
CA2680832A1 (en)	2007-03-27	2008-10-02	Merck & Co., Inc.	Method for detecting autoprocessed, secreted pcsk9
JOP20080381B1 (en)	2007-08-23	2023-03-28	Amgen Inc	Antigen Binding Proteins to Proprotein Convertase subtillisin Kexin type 9 (pcsk9)
EP2361980B1 (en)	2007-10-26	2016-12-07	Dynavax Technologies Corporation	Methods and compositions for inhibition of immune responses and autoimmunity
US8017573B2 (en) *	2007-11-30	2011-09-13	Siemens Healthcare Diagnostics Inc.	Adiponectin receptor fragments and methods of use
AR070316A1 (en)	2008-02-07	2010-03-31	Merck & Co Inc	PCSK9 ANTAGONISTS (SUBTILISINE-KEXINA TYPE 9 PROPROTEIN)
AR070315A1 (en)	2008-02-07	2010-03-31	Merck & Co Inc	ANTIBODIES 1B20 ANTAGONISTS OF PCSK9
WO2010068526A1 (en)	2008-12-12	2010-06-17	Merck Sharp & Dohme Corp.	Pcsk9 immunoassay
CN102596249A (en)	2009-10-30	2012-07-18	默沙东公司	AX1 and AX189 PCSK9 antagonists and variants
CN102639150A (en)	2009-10-30	2012-08-15	默沙东公司	AX213 and AX132 PCSK9 antagonists and variants
AU2011268211B2 (en)	2010-06-16	2015-07-16	Dynavax Technologies Corporation	Methods of treatment using TLR7 and/or TLR9 inhibitors
US8871737B2 (en)	2010-09-22	2014-10-28	Alios Biopharma, Inc.	Substituted nucleotide analogs
EP2655607A4 (en)	2010-12-21	2014-05-14	Univ North Carolina	METHODS AND COMPOSITIONS FOR THE PRODUCTION OF ACTIVE PROTEINS DEPENDENT ON VITAMIN K
CA2860234A1 (en)	2011-12-22	2013-06-27	Alios Biopharma, Inc.	Substituted phosphorothioate nucleotide analogs
WO2013142124A1 (en)	2012-03-21	2013-09-26	Vertex Pharmaceuticals Incorporated	Solid forms of a thiophosphoramidate nucleotide prodrug
WO2013142157A1 (en)	2012-03-22	2013-09-26	Alios Biopharma, Inc.	Pharmaceutical combinations comprising a thionucleotide analog
US8883157B1 (en)	2013-12-17	2014-11-11	Kymab Limited	Targeting rare human PCSK9 variants for cholesterol treatment
US8945560B1 (en)	2014-07-15	2015-02-03	Kymab Limited	Method of treating rheumatoid arthritis using antibody to IL6R
US8986691B1 (en)	2014-07-15	2015-03-24	Kymab Limited	Method of treating atopic dermatitis or asthma using antibody to IL4RA
US9017678B1 (en)	2014-07-15	2015-04-28	Kymab Limited	Method of treating rheumatoid arthritis using antibody to IL6R
US9045548B1 (en)	2014-07-15	2015-06-02	Kymab Limited	Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment
US8980273B1 (en)	2014-07-15	2015-03-17	Kymab Limited	Method of treating atopic dermatitis or asthma using antibody to IL4RA
US8986694B1 (en)	2014-07-15	2015-03-24	Kymab Limited	Targeting human nav1.7 variants for treatment of pain
US9067998B1 (en)	2014-07-15	2015-06-30	Kymab Limited	Targeting PD-1 variants for treatment of cancer
US9051378B1 (en)	2014-07-15	2015-06-09	Kymab Limited	Targeting rare human PCSK9 variants for cholesterol treatment
US9045545B1 (en)	2014-07-15	2015-06-02	Kymab Limited	Precision medicine by targeting PD-L1 variants for treatment of cancer
US9034332B1 (en)	2014-07-15	2015-05-19	Kymab Limited	Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
US9023359B1 (en)	2014-07-15	2015-05-05	Kymab Limited	Targeting rare human PCSK9 variants for cholesterol treatment
US9914769B2 (en)	2014-07-15	2018-03-13	Kymab Limited	Precision medicine for cholesterol treatment
US8992927B1 (en)	2014-07-15	2015-03-31	Kymab Limited	Targeting human NAV1.7 variants for treatment of pain
US9682218B2 (en)	2013-12-23	2017-06-20	Carefusion 2200, Inc.	Pleurodesis device and method
GB201403775D0 (en)	2014-03-04	2014-04-16	Kymab Ltd	Antibodies, uses & methods
US9150660B1 (en)	2014-07-15	2015-10-06	Kymab Limited	Precision Medicine by targeting human NAV1.8 variants for treatment of pain
US9139648B1 (en)	2014-07-15	2015-09-22	Kymab Limited	Precision medicine by targeting human NAV1.9 variants for treatment of pain
EP3471754A1 (en)	2016-06-20	2019-04-24	Kymab Limited	Anti-pd-l1 antibodies
EP3534947A1 (en)	2016-11-03	2019-09-11	Kymab Limited	Antibodies, combinations comprising antibodies, biomarkers, uses & methods
JP7456605B2 (en)	2016-12-23	2024-03-27	プレジデントアンドフェローズオブハーバードカレッジ	PCSK9 gene editing
SG11201909218RA (en)	2017-04-03	2019-11-28	Hoffmann La Roche	Antibodies binding to steap-1
CN110709174A (en)	2017-06-22	2020-01-17	宝洁公司	Film comprising a water-soluble layer and a vapor-deposited organic coating
WO2018237213A1 (en)	2017-06-22	2018-12-27	The Procter & Gamble Company	Films including a water-soluble layer and a vapor-deposited inorganic coating
EP4132591A4 (en)	2020-04-09	2024-04-24	Verve Therapeutics, Inc.	Base editing of pcsk9 and methods of using same for treatment of disease

Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2000004140A1 (en) *	1998-07-15	2000-01-27	Human Genome Sciences, Inc.	71 human secreted proteins
WO2002026931A2 (en) *	2000-09-25	2002-04-04	Human Genome Sciences, Inc.	71 human secreted proteins

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR100236393B1 (en) *	1996-02-02	1999-12-15	나까니시 히로유끼	A pharmaceutical preparation containing a human growth hormone
US5858716A (en) *	1997-05-30	1999-01-12	Smithkline Beecham Corporation	H2CAA71 polynucleotides

2002
- 2002-03-19 CA CA002441755A patent/CA2441755A1/en not_active Abandoned
- 2002-03-19 EP EP02749512A patent/EP1381622A2/en not_active Withdrawn
- 2002-03-19 EP EP02760994A patent/EP1379132A4/en not_active Withdrawn
- 2002-03-19 WO PCT/US2002/009785 patent/WO2002095010A2/en not_active Application Discontinuation
- 2002-03-19 CA CA002441702A patent/CA2441702A1/en not_active Abandoned
- 2002-03-19 EP EP02782476A patent/EP1414845A4/en not_active Withdrawn
- 2002-03-19 AU AU2002363296A patent/AU2002363296A1/en not_active Abandoned
- 2002-03-19 WO PCT/US2002/008123 patent/WO2002102993A2/en not_active Application Discontinuation
- 2002-03-19 CA CA002441416A patent/CA2441416A1/en not_active Abandoned
- 2002-03-19 WO PCT/US2002/008279 patent/WO2002090526A2/en not_active Application Discontinuation
- 2002-03-19 EP EP02799146A patent/EP1390390A4/en not_active Withdrawn
- 2002-03-19 AU AU2002332391A patent/AU2002332391A1/en not_active Abandoned
- 2002-03-19 CA CA002441832A patent/CA2441832A1/en not_active Abandoned
- 2002-03-19 EP EP02759068A patent/EP1404702A4/en not_active Withdrawn
- 2002-03-19 WO PCT/US2002/008124 patent/WO2003004622A2/en not_active Application Discontinuation
- 2002-03-19 WO PCT/US2002/008277 patent/WO2003038063A2/en not_active Application Discontinuation
- 2002-03-19 EP EP02723499A patent/EP1379264A4/en not_active Withdrawn
- 2002-03-19 EP EP02780789A patent/EP1423134A2/en not_active Withdrawn
- 2002-03-19 CA CA002441840A patent/CA2441840A1/en not_active Abandoned
- 2002-03-19 AU AU2002320013A patent/AU2002320013A1/en not_active Abandoned
- 2002-03-19 AU AU2002324424A patent/AU2002324424A1/en not_active Abandoned
- 2002-03-19 WO PCT/US2002/008278 patent/WO2002102994A2/en not_active Application Discontinuation
- 2002-03-19 CA CA002441397A patent/CA2441397A1/en not_active Abandoned
- 2002-03-19 AU AU2002354719A patent/AU2002354719A1/en not_active Abandoned
- 2002-03-19 WO PCT/US2002/008276 patent/WO2002076488A1/en not_active Application Discontinuation
- 2002-03-19 AU AU2002326293A patent/AU2002326293A1/en not_active Abandoned
- 2002-03-19 CA CA002441417A patent/CA2441417A1/en not_active Abandoned

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2000004140A1 (en) *	1998-07-15	2000-01-27	Human Genome Sciences, Inc.	71 human secreted proteins
WO2002026931A2 (en) *	2000-09-25	2002-04-04	Human Genome Sciences, Inc.	71 human secreted proteins

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HSU SHEAU YU ET AL: "Characterization of two LGR genes homologous to gonadotropin and thyrotropin receptors with extracellular leucine-rich repeats and a G protein-coupled, seven-transmembrane region", MOLECULAR ENDOCRINOLOGY, vol. 12, no. 12, December 1998 (1998-12-01), pages 1830 - 1845, XP002528150, ISSN: 0888-8809 *
LOH E D ET AL: "Molecular Characterization of a Novel Glycoprotein Hormone G-Protein-Coupled Receptor", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 282, no. 3, 6 April 2001 (2001-04-06), pages 757 - 764, XP003002810, ISSN: 0006-291X *

Also Published As

Publication number	Publication date
EP1390390A4 (en)	2009-07-08
WO2002090526A3 (en)	2003-10-30
EP1423134A2 (en)	2004-06-02
EP1379264A1 (en)	2004-01-14
AU2002324424A1 (en)	2002-12-03
WO2002102993A3 (en)	2004-03-25
EP1379132A4 (en)	2009-07-01
EP1414845A2 (en)	2004-05-06
EP1390390A2 (en)	2004-02-25
AU2002326293A1 (en)	2003-01-02
EP1414845A4 (en)	2009-07-08
EP1379132A2 (en)	2004-01-14
CA2441417A1 (en)	2002-11-14
WO2003004622A2 (en)	2003-01-16
AU2002363296A1 (en)	2003-05-12
WO2002102994A2 (en)	2002-12-27
WO2002102993A2 (en)	2002-12-27
AU2002332391A1 (en)	2003-01-02
WO2002090526A2 (en)	2002-11-14
AU2002320013A1 (en)	2002-11-18
AU2002354719A1 (en)	2003-01-21
CA2441755A1 (en)	2003-05-08
CA2441397A1 (en)	2002-10-03
EP1379264A4 (en)	2009-07-08
EP1404702A2 (en)	2004-04-07
WO2003038063A3 (en)	2003-12-11
CA2441832A1 (en)	2002-12-27
WO2002095010A2 (en)	2002-11-28
WO2002102994A3 (en)	2003-07-24
WO2002095010A3 (en)	2004-02-12
CA2441840A1 (en)	2002-11-28
EP1381622A2 (en)	2004-01-21
WO2002076488A1 (en)	2002-10-03
CA2441702A1 (en)	2002-12-27
WO2003038063A2 (en)	2003-05-08
WO2003004622A3 (en)	2004-02-19
CA2441416A1 (en)	2003-01-16

Publication	Publication Date	Title
EP1379264A4 (en)	2009-07-08	Human secreted proteins
EP1385381A4 (en)	2005-02-09	Human secreted proteins
GB0218205D0 (en)	2002-09-11	Human ZZAP1 protein
EP1251863A4 (en)	2005-03-02	22 human secreted proteins
AU2002361452A8 (en)	2003-07-09	Secreted proteins
IL162598A0 (en)	2005-11-20	Secreted protein
AU2002232596A1 (en)	2002-06-24	Secreted human proteins
AU2002354803A8 (en)	2008-03-13	Secreted proteins
EP1368468A4 (en)	2005-02-16	83 human secreted proteins
AU2003301843A8 (en)	2004-06-07	157 human secreted proteins
EP1385977A4 (en)	2005-02-16	Secreted proteins
AU2001294719A1 (en)	2002-04-08	Secreted human proteins
EP1370651A4 (en)	2005-04-06	70 human secreted proteins
EP1417224A4 (en)	2005-08-10	Secreted proteins
AU2002365153A1 (en)	2003-06-30	41 human secreted proteins
EP1404807A4 (en)	2005-03-23	20 human secreted proteins
AU2002246998A1 (en)	2002-07-30	50 human secreted proteins
AU2002348034A8 (en)	2009-07-30	16 human secreted proteins
AU2002254275A1 (en)	2002-10-08	Human secreted proteins
AU2002303843A8 (en)	2007-09-20	Secreted proteins
AU2003211136A8 (en)	2003-10-08	6 human secreted proteins
AU2002247189A1 (en)	2002-09-12	70 human secreted proteins
AU2002253985A1 (en)	2002-09-12	83 human secreted proteins
AU2002332483A1 (en)	2003-02-24	13 human secreted proteins
EP1443818A4 (en)	2006-03-08	Novel secreted proteins and their uses

Legal Events

Date	Code	Title	Description
2004-02-20	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2004-04-07	17P	Request for examination filed	Effective date: 20031021
2004-04-07	AK	Designated contracting states	Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR
2004-04-07	AX	Request for extension of the european patent	Extension state: AL LT LV MK RO SI
2009-07-01	RIC1	Information provided on ipc code assigned before grant	Ipc: C07H 21/02 20060101ALI20090527BHEP Ipc: C07K 1/00 20060101AFI20040219BHEP
2009-07-08	A4	Supplementary search report drawn up and despatched	Effective date: 20090605
2010-02-12	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN
2010-03-17	18D	Application deemed to be withdrawn	Effective date: 20090915